首页 | 本学科首页   官方微博 | 高级检索  
     


Raman Microspectroscopic Evidence for the Metabolism of a Tyrosine Kinase Inhibitor,Neratinib, in Cancer Cells
Authors:Karim Aljakouch  Tatjana Lechtonen  Dr. Hesham K. Yosef  Mohamad K. Hammoud  Wissam Alsaidi  Dr. Carsten Kötting  Dr. Carolin Mügge  Prof. Dr. Robert Kourist  Dr. Samir F. El‐Mashtoly  Prof. Dr. Klaus Gerwert
Affiliation:1. http://www.bph.rub.de/ 0000-0002-8330-512X Biophysics Department, Ruhr-University Bochum, Germany;2. Biophysics Department, Ruhr-University Bochum, Germany;3. Junior Research Group for Microbial Biotechnology, Ruhr-University Bochum, Germany;4. Institute of Molecular Biotechnology, Graz University of Technology, Austria
Abstract:Tyrosine kinase receptors are one of the main targets in cancer therapy. They play an essential role in the modulation of growth factor signaling and thereby inducing cell proliferation and growth. Tyrosine kinase inhibitors such as neratinib bind to EGFR and HER2 receptors and exhibit antitumor activity. However, little is known about their detailed cellular uptake and metabolism. Here, we report for the first time the intracellular spatial distribution and metabolism of neratinib in different cancer cells using label‐free Raman imaging. Two new neratinib metabolites were detected and fluorescence imaging of the same cells indicate that neratinib accumulates in lysosomes. The results also suggest that both EGFR and HER2 follow the classical endosome lysosomal pathway for degradation. A combination of Raman microscopy, DFT calculations, and LC‐MS was used to identify the chemical structure of neratinib metabolites. These results show the potential of Raman microscopy to study drug pharmacokinetics.
Keywords:cancer  label-free imaging  metabolism  Raman spectroscopy  tyrosine kinase inhibitors
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号